• Alkermes settled patent litigation with Teva on November 6, 2026, covering all dosage strengths of Lybalvi.
• The agreement grants Teva a non-exclusive, royalty-free license to sell its products in the United States beginning November 12, 2039.
• Pediatric exclusivity would delay entry to May 12, 2040; earlier entry is possible under certain circumstances.
• The parties filed to dismiss the litigation with prejudice on November 9, 2026.
• The settlement is subject to review by the U.S. Federal Trade Commission and Department of Justice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-456888), on November 12, 2026, and is solely responsible for the information contained therein.